Section 16A-14-3 - Research studyNotwithstanding any provision of this act to the contrary, the bureau may, upon application, approve the dispensing of medical cannabis by a clinical registrant to the academic clinical research center for the purpose of conducting a research study. The bureau shall develop the application and standards for approval of such dispensing by the clinical registrant. The following apply to the research study:
(1) The clinical registrant shall disclose the following information to the bureau in its application:(i) The reason for the research project, including the reason for the trial.(ii) The strain of medical cannabis to be used and the strength of the medical cannabis to be used in the research study.(iii) The anticipated duration of the study.(iv) Evidence of approval of the trial by an accredited institutional review board, including any other required regulatory approvals.(v) Other information required by the bureau, except that the bureau may not require disclosure of any information that would infringe upon the academic clinical research center's exclusive right to intellectual property or legal obligations for patient confidentiality.(2) The academic clinical research center shall provide its findings to the bureau within three hundred sixty-five days of the conclusion of the research study or within three hundred sixty-five days of publication of the results of the research study in a peer-reviewed medical journal, whichever is later.(3) The bureau shall allow the exchange of medical cannabis seed between clinical registrants for the conduct of research.Added by 2017 Acts, ch. 195 (SB 386), eff. 4/6/2017.